Contrast in your images. Not in your patients.
The safest choice for your patients
An increasing awareness of the potential risks associated with gadolinium-based contrast agents has revealed the need for alternative, contrast-free MRA techniques. We provide clinicians four generations of unique, non-contrast MRA sequences that minimise risk to patients while producing exceptional images. These images are often better than those acquired with conventional contrast enhanced techniques.
- The safest choice for your patients
- Does not require the use of a contrast agent
- Does not require an IV Injection
Better patient outcomes
Nephrogenic Systemic Fibrosis (NSF) is a debilitating and potentially fatal man-made disease for patients with renal insufficiency who are exposed to gadolinium-based MRI contrast media. Gadolinium is commonly used in contrast enhanced MR Angiography (CE-MRA) exams, because this agent enables rapid scanning over a large field of view at the required high spatial resolution to assess lumen narrowing. Canon’s unique alternative contrast-agent-free angiography techniques provide finely detailed images of the vasculature, improving diagnostic confidence. Non-Contrast MRA is most beneficial for patients with renal insufficiency and vascular disease or suspected vascular disease who are most susceptible to NSF.
(Above) Canon’s unique contrast-agent-free angiography techniques in practice.
Time Space Angiography
(Left) By utilising variable Inversion times, TSA creates non-contrast, time-resolved images with high temporal resolution.
Contrast-free Improved Angiography
Superior imaging of smaller vessels, such as those in the legs, can be achieved using CIA, expanding the window of opportunity for evaluating early disease states.
Spatial Labeling Inversion Pulse
Time-SLIP evaluates hemodynamic velocity, functional assessments, and visualisation of vascular structures.
Fresh Blood Imaging
Using FBI, angiograms and venograms with exceptional sensitivity of the natural blood flow can be obtained in one acquisition.